Novartis (NVS) Stock Forecast & Price Target

Q: What analysts cover Novartis?

Novartis has been rated by research analysts at Citigroup , and Weiss Ratings in the past 90 days.

$163.27 +0.81 (+0.50%)

Closing price 09/3/2026 03:58 PM Eastern

Extended Trading

$160.55 -2.72 (-1.66%)

As of 06:08 AM Eastern

Compare

Novartis - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Hold

Based on 16 Analyst Ratings

Sell
2

Hold
7

Buy
7

Based on 16 Wall Street analysts who have issued ratings for Novartis in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 2 have given a sell rating, 7 have given a hold rating, and 7 have given a buy rating for NVS.

Consensus Price Target

$141.20
-13.52% Downside

According to the 16 analysts' twelve-month price targets for Novartis, the average price target is $141.20. The highest price target for NVS is $180.00, while the lowest price target for NVS is $112.00. The average price target represents a forecasted downside of -13.52% from the current price of $163.27.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for NVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Novartis and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NVS Analyst Ratings Over Time

Type	Current Forecast 9/4/25 to 9/4/26	1 Month Ago 8/5/25 to 8/5/26	3 Months Ago 6/6/25 to 6/6/26	1 Year Ago 9/4/24 to 9/4/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	1 Buy rating(s)
Hold	7 Hold rating(s)	7 Hold rating(s)	7 Hold rating(s)	6 Hold rating(s)
Sell	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)	2 Sell rating(s)
Consensus Price Target	$141.20	$141.20	$141.20	$123.50
Forecasted Upside	-13.52% Downside	-8.67% Downside	-5.26% Downside	-3.88% Downside
Consensus Rating	Hold	Hold	Hold	Hold

NVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Novartis Stock vs. The Competition

Type	Novartis	Healthcare Companies	Broader Market
Consensus Rating Score	2.31	2.30	2.53
Consensus Rating	Hold	Hold	Moderate Buy
Predicted Upside	-13.52% Downside	871.46% Upside	13.67% Upside
News Sentiment Rating	Neutral News See Recent NVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/24/2026	Weiss Ratings 5 of 5 stars		Reiterated Rating	Buy (B)
7/22/2026	Citigroup 4 of 5 stars		Reiterated Rating	Buy
3/26/2026	Morgan Stanley 3 of 5 stars	Mark Purcell Not Rated	Boost Target	Overweight	$143.00 ➝ $170.00	+13.10%
3/19/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold
3/11/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy	$180.00	+11.36%
2/17/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold
2/12/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
2/9/2026	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
1/6/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emmanuel Papada Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underweight ➝ Equal Weight
12/10/2025	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Reduce	$112.00	-14.51%
Get the Latest News and Ratings for NVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.
12/8/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Vosser Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
11/25/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Buy
10/29/2025	Cfra Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Wan Nurhayati Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Hold	$126.00	+2.09%
10/27/2025	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Neutral
10/27/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Leuchten Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
9/12/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Quigley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell	$119.00 ➝ $118.00	-7.54%
4/15/2025	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Verdult Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
2/13/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Weston Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
11/19/2024	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold
10/30/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Market Perform	$118.00 ➝ $120.00	+8.53%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:56 AM ET.

Should I Buy Novartis Stock? NVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 2, 2026. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com.

Novartis
Bull Case

Here are some ways that investors could benefit from investing in Novartis AG:

Novartis AG recently announced that its oral multiple sclerosis drug, remibrutinib, met the primary endpoints in both Phase III REMODEL-1 and REMODEL-2 trials, demonstrating a significant reduction in annualized relapse rates compared to the established treatment teriflunomide. This clinical success, combined with favorable safety profiles and a plan for global regulatory submissions, positions the company to capture a large market opportunity and provides a clear catalyst for future revenue growth.
The stock is currently trading at $162.42, which represents a significant increase from its 52-week low of $121.57 and reflects strong momentum following recent positive news. This price level is supported by a low beta of 0.45, indicating that the stock is less volatile than the broader market, which may appeal to investors seeking stability alongside growth potential in the pharmaceutical sector.
Novartis AG maintains a consistent dividend yield of 2.00%, offering investors a reliable income stream. This is particularly attractive given the company's strong financial health, evidenced by a return on equity of 38.56% and a net margin of 23.29% in its most recent quarterly results, suggesting that the company is efficiently generating profits to support shareholder returns.
The company has secured a significant commercial opportunity through a deal with Alteogen for Hybrozyme, valued at up to $3.2 billion. This agreement expands Novartis AG's portfolio in advanced therapies and provides a substantial potential revenue boost, reinforcing its position as a leader in innovative healthcare solutions and diversifying its income sources beyond traditional small-molecule drugs.
Analyst sentiment remains cautiously optimistic, with a consensus rating of "Hold" and an average price target of $141.20, which, while below the current price, reflects a stable outlook. Recent upgrades from firms like Citigroup and Weiss Ratings, both reaffirming "Buy" ratings in July 2026, indicate that institutional investors recognize the long-term value and strategic positioning of Novartis AG in the global pharmaceutical market.

Novartis
Bear Case

Investors should be bearish about investing in Novartis AG for these reasons:

Novartis AG has paused eight clinical studies of its experimental autoimmune cell therapy, rap-cel, following the deaths of three patients. This safety concern creates significant regulatory and reputational risk, potentially delaying or reducing the commercial value of this pipeline segment and casting a shadow over the company's broader advanced therapy ambitions, despite the positive remibrutinib results.
The current stock price of $162.42 is significantly above the average analyst price target of $141.20, suggesting that the stock may be overvalued relative to consensus expectations. This discrepancy could lead to a price correction if the market reassesses the company's growth trajectory or if the positive impact of recent trial results is already fully priced in, limiting near-term upside potential.
Unusually high put option activity, with 10,827 put options purchased on a single day compared to a typical daily volume of 2,475, indicates that some investors are hedging against potential downside risk. This surge in bearish positioning may reflect concerns about the company's ability to sustain its recent gains or worries about the broader impact of the paused cell therapy trials on overall valuation.
Novartis AG is facing operational challenges in Switzerland, where it may cut approximately 130 jobs in Basel as it relocates laboratory activities and shuts down some production. While this may be part of a cost-efficiency strategy, it could signal short-term disruptions in operations and raise questions about the company's long-term commitment to its European research and development infrastructure.
The company's debt-to-equity ratio of 0.89 and current ratio of 0.86 suggest a moderate level of financial leverage and liquidity constraints. While not immediately alarming, these metrics indicate that Novartis AG may have less financial flexibility to absorb unexpected costs or invest aggressively in new initiatives compared to competitors with stronger balance sheets, particularly if the paused cell therapy trials result in prolonged regulatory delays.

NVS Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Novartis is $141.20, with a high forecast of $180.00 and a low forecast of $112.00.

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.

According to analysts, Novartis's stock has a predicted downside of -13.52% based on their 12-month stock forecasts.

Novartis has been rated by research analysts at Citigroup, and Weiss Ratings in the past 90 days.

Analysts like Novartis more than other "healthcare" companies. The consensus rating score for Novartis is 2.31 while the average consensus rating score for "healthcare" companies is 2.30. Learn more on how NVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Novartis Recommendations

MarketBeat monitors more than a dozen sources for Novartis analyst ratings, with the most recent rating issued on 7/24/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novartis (NVS) Stock Forecast & Price Target